RNS Number : 1498D MaxCyte, Inc. 17 October 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 6329C MaxCyte, Inc. 12 October 2022 MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 ROCKVILLE, MD , October 12, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform
RNS Number : 5404B MaxCyte, Inc. 03 October 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN Total Voting Rights Date: 3 October 2022 : MaxCyte ( Nasdaq: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
RNS Number : 1410A MaxCyte, Inc. 21 September 2022 MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor Expanded facilities illustrate MaxCyte's commitment to Montgomery County and the state of Maryland , building the life sciences community, and propelling
RNS Number : 6658Y MaxCyte, Inc. 08 September 2022 MaxCyte to Participate in Morgan Stanley 20 th Annual Global Healthcare Conference Rockville, MD , September 8, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling
RNS Number : 0087Y MaxCyte, Inc. 01 September 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 September 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 6259V MaxCyte, Inc. 11 August 2022 MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022 ROCKVILLE, MD , August 11, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing
RNS Number : 6262V MaxCyte, Inc. 11 August 2022 MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, MD , August 11, 2022
RNS Number : 6629U MaxCyte, Inc. 02 August 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Rockville, MD - 2 August 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
